Publications
and Scientific Papers
Introduction
Lipid nanoparticle(LNP)-based mRNA vaccines have recently gained traction as an attractive modality for cancer therapies. However, inducing an effective anti-tumor response often requires the induction of a T cell response breaking self-tolerance mechanisms, a challenge forcurrent therapies. Providence Therapeutics has developed next-generation LNP formulations, which can break self-tolerance and have the potential to be utilized for therapeutic LNP/mRNA cancer vaccines.